Dyne Therapeutics, Inc. (DYN)
Nasdaq · Healthcare · Biotechnology
$15.44+1.58%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.9B
- 52-week range
- $12.77 – $27.31
- 52-week change
- +8.96%
- EPS (trailing)
- −$3.30
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$0K
- Diluted EPS
- −$3.47
- Free cash flow
- −$405M
From the company’s annual report on SEC EDGAR.
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Headquarters: Waltham, United States · 289 employees · dyne-tx.com